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Abstract: Signal transducer and activator of transcription 3 (STAT3) is a point of convergence for
numerous oncogenic signals that are often constitutively activated in many cancerous or transformed
cells and some stromal cells in the tumor microenvironment. Persistent STAT3 activation in
malignant cells stimulates proliferation, survival, angiogenesis, invasion, and tumor-promoting
inflammation. STAT3 undergoes activation through phosphorylation on tyrosine 705, which facilitates
its dimerization. Dimeric STAT3 translocates to the nucleus, where it regulates the transcription
of genes involved in cell proliferation, survival, etc. In the present study, a synthetic deguelin
analogue SH48, discovered by virtual screening, inhibited the phosphorylation, nuclear translocation,
and transcriptional activity of STAT3 in H-ras transformed human mammary epithelial MCF-10A
cells (MCF10A-ras). We speculated that SH48 bearing an α,β-unsaturated carbonyl group could
interact with a thiol residue of STAT3, thereby inactivating this transcription factor. Non-electrophilic
analogues of SH48 failed to inhibit STAT3 activation, lending support to the above supposition.
By utilizing a biotinylated SH48, we were able to demonstrate the complex formation between SH48
and STAT3. SH48 treatment to MCF10A-ras cells induced autophagy, which was verified by staining
with a fluorescent acidotropic probe, LysoTracker Red, as well as upregulating the expression of LC3II
and p62. In conclusion, the electrophilic analogue of deguelin interacts with STAT3 and inhibits its
activation in MCF10A-ras cells, which may account for its induction of autophagic death.
Keywords: STAT3; deguelin; SH48; α,β-unsaturated carbonyl group; MCF10A-ras cells; autophagy
Biomedicines 2020, 8, 407; doi:10.3390/biomedicines8100407 www.mdpi.com/journal/biomedicines
Biomedicines 2020, 8, 407 2 of 15
1. Introduction
Growing attention has been focused on the identification of natural products with chemopreventive
and chemotherapeutic potential [1,2]. Deguelin is a natural rotenoid that is isolated from several
medicinal plants, including Derris trifoliata Lour (Leguminosae), Mundulea sericea (Leguminosae),
and Tephrosia vogelii Hook.f (Leguminosae) [3]. Deguelin inhibits the proliferation and growth of
diverse malignant cells, including head and neck [4,5], lung [6], esophageal [7], gastric [8]. colon [9],
pancreatic [10,11], prostate [12], and breast [13,14] cancer cells by targeting multiple signaling molecules.
Although deguelin has promising chemopreventive and chemotherapeutic potential [15,16], undesired
side effects and toxicity limit its clinical application [17,18]. To overcome such limitations, a series of
synthetic analogues of deguelin have been synthesized to evaluate their anticancer activities [19].
Signal transducer and activator of transcription (STAT) family proteins play important roles in cell
growth, survival, and immunity [20–22]. Among these, STAT3 is a transcription factor that is involved
in tumor development and progression as well as inflammation [22–25]. STAT3 is constitutively
activated in several cancer cells [23–26]. The aberrantly activated STAT3 is believed to contribute to
malignant transformation at several levels, including uncontrolled proliferation through activation
of several cell-cycle regulators, (e.g., Cyclin D1 and c-Myc) as well as the evasion of apoptosis by
inducing the expression of anti-apoptotic proteins (e.g., Bcl-xL, Bcl-2, Mcl-1, and Survivin) [24–26].
STAT3 also mediates the expression of proteins involved in other hallmarks of cancer, such as
invasion/metastasis [27] and angiogenesis [28]. Therefore, STAT3 is considered to be an important
target for the development of cancer therapeutic agents [23,25,26,29–33]. The suppression of a STAT3
signal pathway by deguelin has been observed in adult T cells transformed by human T-cell leukemia
virus [34].
Autophagy is a self-eating mechanism [35]. In autophagy, a phagophore engulfs intracellular
organelles or aberrant proteins and then makes autophagosome with microtubule-associated protein
1A/-light chain 3II (LC3II) and p62 [36,37]. Autophagosome fused with lysosomes becomes
autolysosome [36,37]. Autolysosome is eventually degraded, and it supplies nutrition to the
surrounding environment. It has been reported that STAT3 represses autophagy in human cells,
while the inhibition of STAT3 potently stimulates the autophagic flux and thereby affects the fate of
cells [38,39]. In a previous study, a series of deguelin analogues were synthesized to develop novel
STAT3 inhibitors [40]. Here, we report that an electrophilic derivative of deguelin inactivates STAT3




SH48 (M.W. 380.43) and its derivatives were synthesized as described previously [40].
Dulbecco’s modified Eagle’s medium (DMEM)/Ham’s nutrient mixture F-12 (1:1), Rosewell
Park Memorial Institute (RPMI) 1640 medium, Dulbecco’s modified Eagle’s medium (DMEM),
fetal bovine serum (FBS), and horse serum were obtained from Gibco BRL (Grand Island,
NY, USA). Cholera toxin, hydrocortisone, insulin, human epidermal growth factor (h-EGF),
and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were purchased from
Sigma-Aldrich Co. (St. Louis, MO, USA). p-STAT3-TA-Luc plasmid was purchased from BD Biosciences
Clontech (San Jose, CA, USA). Antibodies against p-STAT3, STAT3, LC3II, p62, Bcl-xL, human influenza
hemagglutinin (HA)-tag, and Myc-tag were obtained from Cell Signaling Technology (Beverly,
MA, USA). Agarose immunoprecipitation reagents were products of Santa Cruz Biotechnolgies Co.
(Santa Cruz, CA, USA). Secondary antibodies, STAT3 short interfering RNA (siRNA), negative control
siRNA, and lipofectamin RNAi-MAX reagent were purchased from Invitrogen Life Technologies, Inc.
(Carlsbad, CA, USA). All other chemicals used were of analytical or the highest purity grade available.
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2.2. Cell Culture
MCF10A-ras cells were grown in DMEM/F-12 medium supplemented with 5% heat-inactivated
horse serum, insulin (10 µg/mL), cholera toxin (100 ng/mL), hydrocortisone (0.5 µg/mL), h-EGF
(20 ng/mL), L-glutamine (2 mmol/L), and penicillin/streptomycin (100 units/mL). Human prostate
cancer PC3 cells were cultured in RPMI medium supplemented with 10% (v/v) heat-inactivated FBS,
penicillin (100 U/mL), and streptomycin (100 g/mL). HeLa/STAT3-luc cells were maintained in DMEM
supplemented with 10% FBS and an 100 ng/mL penicillin/streptomycin/fungizone mixture. The cells
were grown at 37 ◦C in a humidified air/CO2 (19:1) atmosphere. The cells were plated at an appropriate
density according to each experimental scale.
2.3. MTT Reduction Assay
The cell viability was determined by the MTT reduction assay. MCF10A-ras cells plated at a density
of 2.5 × 104 cells/200 µL in 48-well plates were treated with SH48 and its analogues. After incubation
for 24 h, cells were treated with the MTT solution (final concentration, 1 mg/mL) for an additional
2 h. The dark blue formazan crystals formed in intact cells were dissolved with dimethyl sulfoxide
(DMSO), and the absorbance at 570 nm was read using a microplate reader.
2.4. Transient Transfection and the Luciferase Reporter Assay
HeLa/STAT3-luc cells were seeded at a density of 2 × 105 per well in a six-well dish and grown to
60% to 80% confluence in the complete growth medium. Cells were pretreated with test compounds
for 24 h and stimulated with 10 ng/mL oncostatin M (OSM) for 5 h. The cells were then washed
with phosphate-buffered saline (PBS) and lysed in 1x reporter lysis buffer (Promega). The lysed cell
extract (20 µL) was mixed with 100 µL of the luciferase assay reagent, and the luciferase activity was
determined using a luminometer (AutoLumat LB 953, EG&G Berthold). The β-galactosidase activity
was measured to normalize the luciferase activity.
2.5. siRNA Knockdown of STAT3.
The human STAT3 siRNA duplex and negative control siRNA were purchased from KDR Biotech
Co., Ltd. (Seoul, South Korea). The sequences of each siRNA were as follows: STAT3 siRNA-1 (sense,
5′UGUUCUCUGAGACCCAUGAdTdT-3′; antisense, 5′-UCAUGGGUCUCAGAGAACAdTdT-3′).
2.6. Western Blot Analysis
MCF10A-ras cells were lysed in lysis buffer (250 mmol/L sucrose, 50 mmol/L Tris-HCl (pH 8.0),
25 mmol/L KCl, 5 mmol/L MgCl2, 1 mmol/L EDTA, 2 mmol/L NaF, 2 mmol/L sodium orthovanadate,
and 1 mmol/L phenylmethylsulfonylfluoride (PMSF)) for 15 min on ice followed by centrifugation
at 13,000× g for 15 min. The BCA reagent (Pierce Biotechnology; Rockfold, IL, USA) was used to
measure the protein concentrations. Protein (30 µg) was separated on 8% sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) gel and transferred to the polyvinylidene fluoride
(PVDF) membrane (Gelman Laboratory; Ann Arbor, MI, USA). The blots were blocked with 5% nonfat
dry milk PBS containing 0.1% (v/v) Tween-20 (PBST) for 1 h at room temperature. The membranes
were incubated for 2 h at room temperature with an 1:1000 dilution of antibodies for p-STAT3,
STAT3, poly (ADP-ribose) polymerase (PARP), Sequestosome 1 (SQSTM1)/p62, Bcl-XL, and LC3B (Cell
Signaling Technology; Beverly, MA, USA). Actin was used to ensure equal lane loading. The blots
were rinsed three times with PBST for 10 min each. Washed blots were treated with an 1:5000 dilution
of horseradish peroxidase (HRP) conjugated-secondary antibody (Pierce Biotechnology; Rockford, IL,
USA) for 1 h and washed again three times with PBST. The transferred proteins were visualized with
an enhanced chemiluminescence detection kit (Amersham Pharmacia Biotech; Buckinghamshire, UK).
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2.7. Immunoprecipitation
After treatment with biotinylated SH48 for 24 h, MCF10A-ras cells were lysed in 250 mmol/L
sucrose, 50 mmol/L Tris-HCl (pH 8.0), 25 mmol/L KCl, 5 mmol/L MgCl2, 1 mmol/L EDTA, 2 mmol/L NaF,
2mmol/L sodium orthovanadate, and 1 mmol/L PMSF. Total protein (500 µg) was immunoprecipitated
by shaking with STAT3 primary antibody at 4 ◦C for 12 h followed by the addition of protein A/G-agarose
bead suspension (25% slurry, 20 mL) and additional shaking for 2 h at 4 ◦C. After centrifugation
at 10,000 rpm for 1 min, immunoprecipitated beads were collected by discarding the supernatant
and washed with cell lysis buffer. The immunoprecipitate was then resuspended in 8 µL of 6 × SDS
electrophoresis sample buffer and boiled for 5 min. Supernatant (48 µL) from each sample was collected
by centrifugation and loaded on SDS-polyacrylamide gel. The incorporation of biotinylated SH48 into
immunoprecipitated proteins was visualized by use of Amersham streptavidin–HRP conjugate.
2.8. Immunocytochemistry
Transfected PC3 cells were plated on the chamber slide at a density of 5 × 104 cells/mL and treated
with SH48 or DMSO. Cells were fixed with 95% methanol/5% acetic acid at −20 ◦C for 5 min, washed
with PBS twice, treated with 0.2% Triton X-100 in PBS for 5 min, and washed with PBST and then with
PBS. Samples were incubated with blocking agent (0.1% Tween-20 in PBS containing 5% bovine serum
albumin (BSA)) at room temperature for 1 h, washed with PBS, and then incubated with a diluted
(1:100) primary antibody for LC3II (Cell Signaling Technology, #2775) overnight at 4 ◦C. After washing
with PBS, samples were incubated with a diluted (1:1000) tetramethylrhodamine (TRITC)-conjugated
anti-mouse or fluorescein isothiocyanate (FITC)-conjugated anti-rabbit IgG secondary antibody in PBST
containing 1% BSA at room temperature for 1 h. Samples were washed with 0.1% PBST containing 1%
BSA and examined under a fluorescent microscope.
2.9. Measurement of the Autophagy
Following treatment, cells were rinsed with PBS and were incubated with 100 nM LysoTracker Red
DND-99 (Thermo Fisher Scientific, Waltham, MA, USA.). After 30 min incubation at 37 ◦C, the cells
were visualized with fluorescence microscopy.
2.10. Molecular Modeling
Binding mode analysis of SH48 was carried out using a covalent docking module implemented
in Maestro program v9.5 (Schrödinger LLC; New York, NY, USA). The crystal structure of STAT3
protein (PDB code: 1BG1) was downloaded from PDB bank. The STAT3 structure was prepared
with neutralization and energy minimization using ProteinPrep Wizard. SH48 was prepared with
protonation at pH 7.4 and energy minimization using LigPrep module. In a covalent docking module,
the reaction type of the ligand was set to Micheal addition with cysteine 259 of STAT3 protein. A grid
box was generated with residues within 5.0 Å of cysteine 259. The 10 initial outputs of the covalent
binding pose were energetically minimized with residues within 3 Å of SH48, and their binding energy
was calculated by Prime MM-GBSA module. The covalent binding pose of SH48 was selected with
low Prime∆Gbind for binding mode analysis.
2.11. Statistical Analysis
Data were expressed as means ± SD of at least three independent experiments, and statistical
analysis for single comparison was performed using the Student’s t-test. The statistical significance
was considered when p < 0.05.
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3. Results
3.1. Comparative Effect of Deguelin Analogues on STAT3 Transcriptional Activity
Several analogues with a modified deguelin skeletal structure (Figure 1) were prepared. To find
out which of these compounds was most effective for suppressing STAT3 signaling, their effects on
STAT3 transcriptional activity were assessed by the luciferase reporter gene assay. The HeLa/STAT3-luc
cell line was pretreated with each compound for 24 h and stimulated with OSM (10 ng/mL) for an
additional 5 h. As shown in Figure 2A, SH48 was found to be the most potent inhibitor of STAT3
transcriptional activity.
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substitution in a double bond with hydrogen in comparison with SH48. SH43 has a single bond. As 
with SH48, SSI1204 has an α,β-unsaturated carbonyl moiety (Figure 3A). SSI1205 has a substitution 
in the carbonyl group with a hydroxyl group and some addition in a benzene ring (Figure 3A). Then, 
the protein expression of p-STAT3 as well as STAT3 was measured by Western blot analysis. As 
shown in Figure 3B, STAT3 phosphorylation was significantly decreased by treatment with SH48 and 
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Figure 2. Effects of deguelin analogues on transcriptional activity, nuclear localization and dimerization
of signal transducer and activator of transcription 3 (STAT3). (A) HeLa/STAT3-luc cells were pretreated
with dimethyl sulfoxide (DMSO) or each of analogues (10 µM) for 24 h, stimulated with 10 ng/mL
of oncostatin M (OSM) for another 5 h, and then assayed for the luciferase reporter gene activity as
described in Section 2. * p < 0.05; *** p < 0.001. (B) Immunocytochemical analysis was performed using
p-STAT3Y705 antibody after the treatment of MCF10A-ras cells with 10 µM SH48 for 24 h. Cells were
stained with PI and visualized by confocal microscopy. Scale bar, 50 µm. (C) Immunocytochemical
analysis was performed using HA-tag and Myc-tag antibodies. PC3 cells were treated with 10 µM
SH48 for 24 h. Cells were stained with DAPI and analyzed by confocal microscopy. Scale bar, 50 µm.
STAT3 phosphorylation at the tyrosine 705 residue facilitates STAT3 dimer formation, leading
to nuclear translocation and binding to a specific DNA site to regulate target gene transcription [5].
Therefore, the inhibition of the homodimerization of STAT3 has been considered as a rational strategy
in the management of cancer [41]. STAT3 phosphorylated at th tyrosine 705 (p-STAT3Y705) stained
with FITC-conjugated anti-r bbit IgG antibody was visualized as green fluorescence. The result of
immunocytochemistry sh w d that SH48 treatment reduced the levels of p-STAT3Y705 and its nuclear
translocation at the same concentration which inhibited STAT3 transcriptional ctivity (Figure 2B).
In another experiment, STAT3 was tagge with HA and Myc. HA-tagged STAT3 was detected by
green fluorescence, and Myc-tagged STAT3 was indicated by red fluorescence. The n clear marker
DAPI was shown in blue fluorescence. In SH48-treated cells, a bright lue color of the nucleus was
seen, while reen or red colors were less intense (Figure 2C). These findings suggest that SH48 inhibits
TAT3 dimerization a d transl cation into the n cleus.
3.2. The α,β-Unsaturated Carbonyl Moiety of SH48 Is Essential for the Inhibition of STAT3 Phosphorylation
It is known that the α,β-unsaturated carbonyl group is required for the inhibition of STAT3
phosphorylation by some chalcone derivatives [42]. MCF10A-ras cells were treated with a 5 µM
concentration of SH48, SH42, SH43, SSI1204, or SSI1205 for 24 h. SH42 has a substitution in a double
bond with hydrogen in comparison with SH48. SH43 has a single bond. As with SH48, SSI1204
has an α,β-unsaturated carbonyl moiety (Figure 3A). SSI1205 has a substitution in the carbonyl
group with a hydroxyl group and some addition in a benzene ring (Figure 3A). Then, the protein
expression of p-STAT3 as well as STAT3 was measured by Western blot analysis. As shown in Figure 3B,
STAT3 phosphorylation was significantly decreased by treatment with SH48 and SSI1204 harboring
an electrophilic α,β-unsaturated carbonyl moiety. However, total STAT3 expression was not affected
(Figure 3B). In parallel with the inhibition of STAT3 phosphorylation, both SH48 and SSI1204 reduced
the viability of MCF10A-ras cells, whereas the other analogues without an electrophilic moiety were
not cytotoxic (Figure 3C).
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(A) Chemical structures of SH48 and SH1203 and their non-electrophilic analogues. Red and green circles
denote electrophilic carbonyl and non-electrophilic alcoholic functions, respectively. (B) MCF10A-ras
cells were treated with 5 µM each of SH48 SH42, SH43, SSI-1204, and SSI-1205 for 24 h, and the
expression of P-STAT3 and STAT3 was measured by Western blot analysis. Actin was measured for the
confirmation of the equal amount of loaded protein. ** p < 0.01; *** p < 0.001. (C) MCF10A-ras ells
wer treated with indicated concentrations of SH42, SH43, SH48, SSI1204, and SSI12 5 for 24 h. The cell
viability was measured by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay as described in Section 2. * p < 0.05; *** p < 0.001.
3.3. SH48 Forms a Complex with STAT3
To demonstrate the direct interaction between STAT3 and SH48, a biotinylated SH48 was used
(Figure 4A). The binding of biotin-conjugated SH48 to STAT3 was detected with HRP–streptavidin
(Figure 4B). T eatment with the thiol-reducing agent dithiothreitol (DTT) abolished the interaction
between SH48 a STAT3 (Figure 4B), suggesting the possible modifica ion of STAT3 cysteine thiol
by SH48. Likewise, the SH48-induced s ppression of STAT3 phosphorylation was attenuated by
DTT (Figure 4C) and also by another thiol-reducing agent and N-acetylcysteine (NAC) (Figure 4D).
This observation suggests a possible interaction of SH48 with a cysteine residue present in STAT3.
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MCF10A-ras cells were pretreated with 0.5 mM dithiothreitol (DTT) for 1 h and treated with the biotin
conjugate of SH48 (30 µM) for an additional 24 h. T e complex formed between the biotin-conjugate of
SH48 to STAT3 was detected by immunoblot analysis using horseradish peroxidase (HRP)–streptavidin.
** p < 0.01; *** p < 0.001. (C,D) MCF10A-ras cells were pretreated with 0.5 mM DTT (C) or 5 mM
N-acetylcysteine (NAC) (D) for 1 h, followed by exposure to SH48 (10 µM) for additional 24 h.
The interaction between STAT3 and SH48 was assessed as described above. ** p < 0.01; *** p < 0.001.
3.4. Cysteine 259 of STAT3 Is a Putative Binding Site of SH48
There are 14 cysteine residues present in human STAT3 (Figure 5A). A computer structure
modeling program showed the cysteine 259 residue of STAT3 to be a putative binding site of SH48
(Figure 5B). An interaction between SH48 and Cys259 of STAT3 was anticipated based on the fact that
this mino acid is located in the short loop between helices α2 and α3 of the amino-terminal four-helix
bundle of STAT3, which lies against the core β-barrel of the monomer. Therefore, Cys259 is exposed in
the surface of the tertiary structure of STAT3 (Figure 5B) and considered to be prone to disulfide bridge
formation upon oxidative stress [43]. The mass spectrometric analysis also indicated an interaction
between SH48 and Cys259 of STAT3 (Figure 6).
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3.5. SH48 Induces Autophagy
The suppression of STAT3 has been shown to induce apoptosis [44]. We determined whether a
cytotoxic dose of SH48 could induce the apoptosis of MCF10A-ras cells overexpressing STAT3; however,
we were unable to detect hallmarks of apoptosis, such as the cleavage of PARP and reduction in the
levels of the anti-apoptotic protein Bcl-xL (Figure 7A). For this reason, SH48-induced cell death is
unlikely to be mediated by apoptosis.
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Figure 7. Induction of autophagy by SH48. (A) MCF10A-ras cells were treated with SH48 for 24 h.
Lysates were immunoblotted with the indicated antibodies. (B) MCF10A-ras cells were treated with
indicated concentrations of SH48 for 24 h and then incubated with 100 nM LysoTracker Red for 30 min.
The cells undergoing autophagic death were identified by FACS analysis. (C) SH48-induced expression
of autophagy marker proteins, LC3II and p62 by Western blot analysis. ** p < 0.01; *** p < 0.001.
(D) Effects of the thiol-reducing agent DTT on SH48-induced STAT3 phosphorylation and p62 expression.
MCF10A-ras cells pretreated with 0.5 mM DTT for 1 h, followed by 10 µM SH48 for 24 h. (E) Direct
interaction between p62 and its inhibition by SH48. MCF10A-ras cells were treated with indicated
concentrations of SH48 for 24 h. Protein lysates were immunoprecipitated with STAT3 antibody
followed by Western blot analysis with anti-p62 antibody.
Autophagy is a self-eating mechanism whereby cells digest themselves uring starvation.
During autophagy, the intracellular phagophore engulfs misfolded proteins of cellular organelles and
then forms autophagosome. Autophagic vesicles and their contents are destroyed by the fusion of
lysosomes. The role of autophagy in cancer is complex. Autophagic vesicles reflect the existence
of type-II cell death, or instead an adaptive response to maintain continual cell survival under
stress condition [45]. It is known that STAT3 can interfere with autophagic pathways, and that the
suppression of STAT3 induces autophagy [38,39]. SH48-induced autophagic cell death was assessed by
flowcytometric analysis of autolysosome formation using a fluorescent acidotropic probe LysoTracker
Red (Figure 7B). In addition, SH48 treatment resulted in an increased accumulation of the autophagic
markers LC3II and p62 as determined by Western blot analysis (Figure 7C).
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In contrast to SH48, which bears an α,β-unsaturated carbonyl moiety and hence is capable of
directly binding to the STAT3, the non-electrophilic analogues SH42 and SH43, which lack such
an electrophilic moiety, failed to suppress STAT3 phosphorylation and upregulate p62 expression.
Moreover, the SH48-induced accumulation of p62 was abolished by DTT treatment (Figure 7D).
Thus, the α,β-unsaturated carbonyl group of SH48 is likely to be important in terms of its induction
of autophagy as well as STAT3 inhibition. In an attempt to determine the association between the
inhibition of STAT3 signaling and the induction of autophagy by SH48, the interaction between
p62 and STAT3 by immunoprecipitation was examined. As shown in Figure 7E, we found a novel
binding between STAT3 and p62 in MCF10A-ras cells. SH48 treatment suppressed this interaction in a
concentration-dependent manner (Figure 7E).
To investigate the functional importance of Cys259 of STAT3 for SH48-induced autophagy,
genetically engineered STAT3 proteins were created and transduced in STAT3-null PC-3 cells.
SH48-induced autophagy was verified by the staining of LC3II (Figure 8A) and LysoTracker (Figure 8B).
However, these events were not evident in mutant cells, in which Cys259 of STAT3 was replaced to
alanine (Figure 8).
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transfected with a mock vector or an expression vector for HA-STAT3WT or mutant STAT3C259A for
18 h. (A) The cells were treated with SH48 (10 µM) for 24 h, The transfected cells were treated with
DMSO or SH48 for 24 h, and then stained for LC3II (A) or lysotracker (B). Scale bar, 100 µm.
4. Discussion
Constitutive overactivation of STAT3 is known to be implicated in the pathogenesis of tumor
development and progression [22–28]. Theref re, he inhibit on of abnormally levated STAT3
activity or expression represe ts a rational th rapeu ic modali y for m lignancies, including breast
cancer [23,25,26,29–33,46]. The blockage of ab rant STAT3 act vati n by ge etic or pharmacological
approaches has been achieved by the use of small molecular we ght inhibitors, protein inhibitors,
dominant-negativ STAT3 mutants, antisense RNA, and interference ol gonucleotides (RNAi).
N tural products and their synthetic analogues have be n id ntified as important sources of
developing STAT3 inhibitors [47]. For instance, curc min, betulinic acid, capsaicin, caffeic acid, celastr l,
cucurbitacins, guggulsterone, diosgenin, and honokiol are known to be natural STAT3 inhibitors [47].
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Deguelin, a rotenoid isolated from several tropical plants of the Leguminosae family, was reported to
inhibit STAT3 signaling, which accounts for its antiproliferative activity towards some transformed
and cancerous cells [4–16]. In an attempt to enhance its efficacy while minimizing the side effects,
a series of analogues of deguelin have been synthesized and tested for their capabilities to suppress
STAT3 activation [40]. Among them, an electrophilic analogue, SH48, bearing an α,β-unsaturated
carbonyl group was found to be most potent in terms of inhibiting the transcriptional activity of STAT3.
However, the mechanisms underlying SH48-induced STAT3 inhibition have not been fully elucidated.
Therefore, we intended to conduct an experiment to determine the effects of SH48 on upstream events
of STAT3 activation in MCF10A-ras cells.
SH48 has a structure that is similar to that of deguelin as it bears an electrophilic α,β unsaturated
carbonyl moiety. Unlike deguelin, however, the double bond conjugated to the carbonyl group
of SH48 is not incorporated into the aromatic ring but present in a truncated B,C ring (Figure 1).
The phosphorylation of STAT3 at the tyrosine705 residue is known to be a crucial event for its activation.
As SH48 does not greatly influence the activation of upstream kinases, such as Jaus kinase 2 (JAK2),
involved in STAT3 phosphorylation, we speculated that the compound SH48 could form a complex
with STAT3, presumably at a critical thiol residue, thereby suppressing the phosphorylation and
subsequent dimerization of STAT3. The STAT3 dimer is formed via the reciprocal interaction between
the SH2 domain of one monomer and the phosphorylated tyrosine of the other. We speculate that
the interaction of SH48 with cysteine 259 of STAT3 hampers the access of an upstream kinase to Y705
for phosphorylation.
It is well known that STAT3 is involved in the transcriptional regulation of genes encoding apoptosis
inhibitors (e.g., Bcl-xL) and cell-cycle regulators (e.g., Cyclin D1) [24–26]. However, the SH48-induced
suppression of STAT3 did not lead to apoptosis but rather induced autophagy in MCF10A-ras cells.
The induction of autophagic cell death by SH48 was verified by the upregulation of LC3II and p62,
which are the autophagy markers. LC3II and p62 constitute autophagosome, which is an important
factor in autophagic signaling.
As autophagy progresses, autophagosome is fused with lysosome and degraded.
Thus, the accumulation of p62 is anticipated to be reduced as autophagy terminates [48,49]. In line
with this speculation, the expression level of p62 was shown to increase until 24 h and gradually
decrease by 36 h (S.-J. Hong, unpublished observation). When autophagosome is degraded, LC3II
maintains a constant level because LC3II is degraded to a lesser extent than p62 during the destruction
of autophagosome.
SH48 has an α,β-unsaturated carbonyl moiety which can mediate the process of Michael addition
between SH48 and STAT3. Although our study suggests that SH48 inhibits STAT3 by Michael addition,
hydrogen bonding may also be involved. This is a weak force but has enough energy to induce
a reaction between molecules. Therefore, the cell viability was compared after treatment with an
equimolar concentration of SH48 and SSI1205, which are incapable of interacting with STAT3 via
H-bonding. However, the H-bond is unlikely to contribute to the inactivation of STAT3.
In summary, the synthetic deguelin analogue SH48 inhibits the phosphorylation, DNA-binding
activity, and transcriptional activity of STAT3, leading to the induction of autophagy in MCF10A-ras
cells (Figure 9). SH48 induces autophagy in MCF10A-ras cells but not in MCF10A normal cells.
Structure–activity analysis revealed that the α,β-unsaturated carbonyl moiety of SH48 is essential for
its complex formation with STAT3 and consequent inactivation of this oncogenic transcription factor.
Further studies will be necessary to clarify the direct interaction of SH48 with STAT3 by using more
sophisticated physicochemical techniques.
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